Current Issue 2018  Archive 2017 

Editor-in-Chief of OBM Hepatology and Gastroenterology

Osamu Yokosuka is an Emeritus Professor of Chiba University, Japan. He graduated from Chiba University School of Medicine in 1975 then worked as a trainee under Professor K. Okuda in Chiba University Hospital till 1978. Dr. Yokosuka was a research fellow worked under Professor S. Scherlock and Professor B. H. Billing in Royal Free Hospital, London, UK from 1978 to 1980; under Professor M. Omata in Chiba University from 1980 to 1985; and under Dr. J Summers in Fox Chase Cancer Center, PA, USA in 1984. In 1985, he received a Degree of Doctor of Medical Science, and served as an Assistant Professor in Chiba University till 1994, then as Lecturer in Medicine till 2006 when he was appointed as Director and Professor of Medicine. From 2013 to 2015, he served as the Dean of Chiba University School of Medicine.

Dr. Yokosuka was the Secretary General of APASL (2008-2014). In 2016, he was elected as the President of APASL Tokyo, the President of 52nd Annual Meeting of Japan Society of Hepatology, and the President of Funabashi Central Hospital. Dr. Yokosuka’s research mainly focuses on Hepatitis and Hepatocellular Carcinoma. So far, he has published more than 700 original papers.


The Associate Editor of OBM Hepatology and Gastroenterology

Tatsuo Kanda received a medical degree in 1991 at Niigata University School of Medicine, Japan, and his PhD in 1999 at Chiba University Graduate School of Medicine, Japan. He had post-doctor training for 3 years under Prof. Ratna Ray and Prof. Ranjit Ray at Saint Louis University, St. Louis, MO, USA. In Dec. 2008, Tatsuo Kanda became a Tenure-track Associate Professor at Department of Medicine and Clinical Oncology, Chiba University, Graduate School of Medicine, Japan. In Feb. 2013, Tatsuo Kanda was nominated a permanent Associate Professor at Department of Gastroenterology and Nephrology, Chiba University, Graduate School of Medicine, Japan. In 2017, Tatsuo Kanda became an Associate Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nihon University School of Medicine. For ~25 years, he has focused his scientific interests on the topics related to liver diseases including acute liver failure, viral hepatitis and autoimmune liver diseases, and worked with Prof. Osamu Yokosuka. Tatsuo Kanda is also an expert for hepatitis A virus (HAV), HBV and HCV, and translation and replication of these viruses, and hepatocarcinogenesis. With his expertise in antiviral therapies and hepatitis virus research, Tatsuo Kanda also sees a lot of patients in clinical daily practice. Tatsuo Kanda has published more than 200 articles in peer-reviewed Journal.

Special Issue

Fundamental Interventions: Revolutions in Geriatric Disease

Submission Deadline: January 31, 2017 (Open)               Submit Now

Guest Editor

Michael Fossel, MD, PhD
1. President of Telocyte (
2. Retired Clinical Professor of Medicine, Michigan State University, Lansing, MI, USA
E-Mail: [email protected]; [email protected]
Research Interests: human aging; telomeres; telomerase therapy; age-related diseases; Alzheimer's disease

Photo by courtesy of University of Kansas Medical Center.

About This Topic

Dear Colleagues:

Geriatrics is entering a revolutionary era. This journal will introduce both the rationale for, and the upcoming innovations of, that new era. Until now, geriatrics has been a largely descriptive endeavor, focusing on medical and nursing interventions which alleviate but do not cure or prevent age-related disease. This has been due both to our shallow understanding of the aging process and to the limitations of small-molecule therapies. In this issue, we will introduce both a deeper understanding of disease and the burgeoning and innovative therapies that are coming into clinical use. This deeper understanding, coupled with novel, biological interventions, promises to take geriatrics into an unprecedented era, in which we can both prevent and cure age-related diseases.

This deeper understanding encompasses not merely genetics, but regulatory epigenetics; not merely small molecules, but “large molecular” approaches, such as gene therapy; not merely biologically active molecules, but human cells themselves, such as stem and other cell therapies. Perhaps most importantly, we have finally begun to understand the role of changing gene expression, along with the key modulatory role played by telomere shortening, in human age-related disease. None of these concepts or their related interventions are simple or straightforward. They demand a sophisticated understanding of biology, pathology, genetics, and clinical medicine. On the other hand, it is far too easy to use a facile assessment of these topics, making unwarranted claims based on little knowledge and less thought. The literature is replete with invalid and unreliable conclusions, yet the underlying promise remains: we are on the verge of successfully intervening in age-related diseases, with efficacy and compassion.

We encourage articles that reflect this insight, that portray the mechanisms, and that evaluate the actual potential of 21st century medicine as we finally advance upon the most difficult of human diseases, those of geriatric medicine.



The Feasibility and Necessity of a Revolution in Geriatric Medicine Giacinto Libertini

Giacinto Libertini
Received: February 20, 2017; Published: April 17, 2017; doi:10.21926/obm.geriat.1702002